Evidence map›Paper›PMID 31804317›Full record

Observational studyMedicine2019

Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013.

Angela C Tramontano, Yufan Chen, Tina R Watson, Andrew Eckel, Deirdre F Sheehan, Mary Linton B Peters, Pari V Pandharipande, Chin Hur, Chung Yin Kong

Abstract readObservational Study
In one paragraph

Observational study in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. SupplementalCancers · 2021
    Article
  9. Pancreatic Cancer in High-Income Asia-Pacific: A Population-Based Study.Cancer control : journal of the Moffitt Cancer Center
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Angela C TramontanoInstitute for Technology Assessment, Massachusetts General Hospital, Boston, MA.
Yufan ChenInstitute for Technology Assessment, Massachusetts General Hospital, Boston, MA.
Tina R WatsonInstitute for Technology Assessment, Massachusetts General Hospital, Boston, MA.
Andrew EckelInstitute for Technology Assessment, Massachusetts General Hospital, Boston, MA.
Deirdre F SheehanInstitute for Technology Assessment, Massachusetts General Hospital, Boston, MA.
Mary Linton B PetersInstitute for Technology Assessment, Massachusetts General Hospital, Boston, MA.
Pari V PandharipandeInstitute for Technology Assessment, Massachusetts General Hospital, Boston, MA.
Chin HurColumbia University Medical Center, New York City, NY.
Chung Yin KongInstitute for Technology Assessment, Massachusetts General Hospital, Boston, MA.

Funding

Optimizing the Treatment of Pancreatic AdenocarcinomaR01CA212086 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HUR, CHIN, KONG, CHUNG YIN · 2017 to 2021
$2.1M
NCI NIH HHS R01 CA212086
6 · The paper itself

Abstract

objectivesOur study provides phase-specific cost estimates for pancreatic cancer based on stage and treatment. We compare treatment costs between the different phases and within the stage and treatment modality subgroups.

methodsOur cohort included 20,917 pancreatic cancer patients from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database diagnosed between 2000 and 2011. We allocated costs into four phases of care-staging (or surgery), initial, continuing, and terminal- and calculated the total, cancer-attributable, and patient-liability costs in 2018 US dollars. We fit linear regression models using log transformation to determine whether costs were predicted by age and calendar year.

resultsMonthly cost estimates were high during the staging and surgery phases, decreased over the initial and continuing phases, and increased during the three-month terminal phase. Overall, the linear regression models showed that cancer-attributable costs either remained stable or increased by year, and either were unaffected by age or decreased with older age; continuing phase costs for stage II patients increased with age.

conclusionsOur estimates demonstrate that pancreatic cancer costs can vary widely by stage and treatment received. These cost estimates can serve as an important baseline foundation to guide resource allocation for cancer care and research in the future.

Indexed as

AgedAged, 80 and overAge FactorsFemaleHealth ExpendituresHumansLinear ModelsMaleMedicareModels, EconometricNeoplasm StagingPancreatic NeoplasmsSEER ProgramTerminal CareUnited States

Identifiers

PMID31804317
PMCPMC6919520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.